Advanced BioHealing, Inc. News
Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
WEST PORT, Conn., and
"Since launching Dermagraft in 2007, we have seen the need for a focused commercial presence within government healthcare systems," said
Dermagraft is a bioengineered tissue product approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers (DFUs). DFUs, a complication of diabetes, affect more than 400,000 people every year in the US. If not treated properly, DFUs can result in serious infection, sometimes resulting in the need for partial or full limb amputation. There are over 100,000 amputations performed annually in the US with more than 80% owing their origin to uncontrolled infection.
"There are many wound care companies that would enjoy the opportunity to promote a product like Dermagraft," says
Regenesis developed and now markets the Provant(R) Wound Therapy System. Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics. For more information about Regenesis Biomedical visit http://www.Regenesisbiomedical.com
About Advanced BioHealing, Inc.
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with corporate offices in West Port, CT and manufacturing operations in
For more information about Dermagraft visit http://www.Dermagraft.com Contacts: Advanced BioHealing, Inc. Dean Tozer VP Marketing & Corporate Development DTozer@AdvancedBioHealing.com 615-260-3770 Regenesis Biomedical, Inc. Media: Scott Robey, VP Marketing robey@regenesisbiomedical.com Clinicians: Rick Isenberg, MD, VP Clinical Affairs isenberg@regenesisbiomedical.com Investors: Virginia Rybski, Acting President rybski@regenesisbiomedical.com www.regenesisbiomedical.com 480-970-4970
SOURCE Regenesis Biomedical, Inc.; Advanced BioHealing, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
